(9ci)-2-甲基-4-(1-甲基乙基)-1H-苯并咪唑 | 134068-85-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: (9ci)-2-甲基-4-(1-甲基乙基)-1H-苯并咪唑
• 英文名称: 7-Isopropyl-2-methyl-1H-benzo[D]imidazole
• 英文别名: 2-methyl-4-propan-2-yl-1H-benzimidazole
• CAS: 134068-85-2
• 化学式: C₁₁H₁₄N₂
• mdl: MFCD09955634
• 分子量: 174.24
• InChiKey: CIIJRIOZLWEWJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] 2-(2-AZABICYCLO[3.1.0]HEXAN-1-YL)-1H-BENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-(2-AZABICYCLO [3.1.0] HEXAN-1-YL)-1H-BENZIMIDAZOLE
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2020007964A1

  公开（公告）日：2020-01-09

  The present invention relates to compounds of the Formula (I) wherein Ar1, R1, and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式（I）的化合物，其中Ar1，R1和（R5）n如描述中所述，以及它们的制备，其药学上可接受的盐，以及它们作为药物的用途，包括含有一种或多种式（I）化合物的药物组合物，特别是它们作为促进睡眠的奥莱欣受体拮抗剂的用途。
• NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS
  申请人：Roberts Edward

  公开号：US20100010001A1

  公开（公告）日：2010-01-14

  Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-4-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.

  提供了激活1型鞘氨醇-1-磷酸受体的化合物。某些化合物在与鞘氨醇-4-磷酸受体亚型3相比，选择性地激活受体亚型1。提供了用于治疗需要医学上激活、激动、抑制或拮抗S1P1的恶性疾病的创新化合物的用途和方法。
• BENZIMIDAZOLE-PROLINE DERIVATIVES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20150166527A1

  公开（公告）日：2015-06-18

  The present invention relates to compounds of the formula (I) wherein Ar 1 , R 1 , R 2 , R 3 , R 4a , R 4b and (R 5 ) n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的化合物，其中Ar1，R1，R2，R3，R4a，R4b和（R5）n如描述中所述，以及它们的制备，其药学上可接受的盐，以及它们作为药物的用途，包括含有一个或多个公式（I）化合物的药物组合物，特别是它们作为促进睡眠激素受体拮抗剂的用途。
• [EN] BENZIMIDAZOLE-2-METHYL-MORPHOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE-2-MÉTHYL-MORPHOLINE
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：WO2020099511A1

  公开（公告）日：2020-05-22

  The present invention relates to compounds of the Formula (I) wherein Ar1, R1, and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式（I）的化合物，其中Ar1，R1和（R5）n如描述所述，其制备方法，其药学上可接受的盐以及其作为药物的用途，含有一个或多个式（I）化合物的药物组合物，特别是它们作为促进睡眠的药物。
• [EN] KRAS G12D INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12D
  申请人：JINGRUI BIOPHARMA CO LTD

  公开号：WO2022262686A1

  公开（公告）日：2022-12-22

  Disclosed are novel compounds which are KRAS G12D inhibitors, their synthesis and their use for treating diseases or conditions, such as cancer, and in particular for inhibiting the activity of KRAS G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

  本发明涉及新的化合物，它们是KRAS G12D抑制剂，其合成以及用于治疗疾病或病况的方法，例如癌症，特别是用于抑制KRAS G12D的活性，药物组合物包括这些化合物和使用方法。